Contributions
Abstract: P893
Type: Poster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Grey matter (GM) damage has been widely recognized as a fundamental aspect of multiple sclerosis (MS). Among several measures of GM disease, cortical lesions (CLs) burden, which can be detected at MRI scans with double inversion recovery (DIR) sequences, has been demonstrated to correlate with cognitive impairment (CI), an important component of MS disability.
Aims: To investigate the role of total and regional CLs number in predicting CI in a cohort of relapsing-remitting and progressive MS patients.
Methods: Thirty consecutive MS patients presenting CLs (CL+) at high-field (3T) MRI 3D-DIR sequences and an even group of MS patients without CLs (CL-) as a control, were investigated with the Rao Brief Repeatable Battery of Neuropsychological Tests (BRB), Version A plus Stroop Test. Total and regional CLs number were computed in all patients.
Results: Among the sixty MS patients enrolled, forty-seven (78.3%) had a relapsing-remitting course, while thirteen (21.7%) a progressive one. Compared to CL-, CL+ patients had a significantly higher (p=0.04) EDSS score and a greater proportion of progressive forms (p = 0.03). The most affected lobe was the frontal lobe (73.3% of patients), followed by temporal and parietal ones (both 60.0%). Total CLs number was higher in the progressive forms (p=0.03). Univariate analysis revealed a significant correlation between total CLs number and deficit at SRT-LTS (p=0.02), SRT-CLTR (p< 0.001), PASAT 3 (p=0.004), SRT-D (p< 0.001), SPART-D (p< 0.001). Similar results were found for frontal and temporal lobes. Multivariate analysis revealed total CLs number as an independent predictor of deficit at SRT-LTS (p=0.01) and PASAT 3 (p=0.05).
Conclusions: We confirmed the important role of CLs number, evaluated with a technique quite commonly available in clinical practice, in predicting CI in MS patients, in order to make an early diagnosis and monitor the evolution of CI and the potential neuroprotective effects of novel drugs.
Disclosure: E. Curti: nothing to diclose.
S. Graziuso: nothing to disclose.
E. Tsantes: nothing to disclose.
G. Crisi: nothing to disclose.
F. Granella: nothing to disclose.
Abstract: P893
Type: Poster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Grey matter (GM) damage has been widely recognized as a fundamental aspect of multiple sclerosis (MS). Among several measures of GM disease, cortical lesions (CLs) burden, which can be detected at MRI scans with double inversion recovery (DIR) sequences, has been demonstrated to correlate with cognitive impairment (CI), an important component of MS disability.
Aims: To investigate the role of total and regional CLs number in predicting CI in a cohort of relapsing-remitting and progressive MS patients.
Methods: Thirty consecutive MS patients presenting CLs (CL+) at high-field (3T) MRI 3D-DIR sequences and an even group of MS patients without CLs (CL-) as a control, were investigated with the Rao Brief Repeatable Battery of Neuropsychological Tests (BRB), Version A plus Stroop Test. Total and regional CLs number were computed in all patients.
Results: Among the sixty MS patients enrolled, forty-seven (78.3%) had a relapsing-remitting course, while thirteen (21.7%) a progressive one. Compared to CL-, CL+ patients had a significantly higher (p=0.04) EDSS score and a greater proportion of progressive forms (p = 0.03). The most affected lobe was the frontal lobe (73.3% of patients), followed by temporal and parietal ones (both 60.0%). Total CLs number was higher in the progressive forms (p=0.03). Univariate analysis revealed a significant correlation between total CLs number and deficit at SRT-LTS (p=0.02), SRT-CLTR (p< 0.001), PASAT 3 (p=0.004), SRT-D (p< 0.001), SPART-D (p< 0.001). Similar results were found for frontal and temporal lobes. Multivariate analysis revealed total CLs number as an independent predictor of deficit at SRT-LTS (p=0.01) and PASAT 3 (p=0.05).
Conclusions: We confirmed the important role of CLs number, evaluated with a technique quite commonly available in clinical practice, in predicting CI in MS patients, in order to make an early diagnosis and monitor the evolution of CI and the potential neuroprotective effects of novel drugs.
Disclosure: E. Curti: nothing to diclose.
S. Graziuso: nothing to disclose.
E. Tsantes: nothing to disclose.
G. Crisi: nothing to disclose.
F. Granella: nothing to disclose.